These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 30300141)

  • 121. Revisiting checkpoint inhibitors for myeloma: maintenance after stem cell transplant.
    Meermeier EW; Bergsagel PL
    J Clin Invest; 2023 Feb; 133(4):. PubMed ID: 36787254
    [TBL] [Abstract][Full Text] [Related]  

  • 122. Prognostic Relevance of Multi-Antigenic Myeloma-Specific T-Cell Assay in Patients with Monoclonal Gammopathies.
    Lagreca I; Nasillo V; Barozzi P; Castelli I; Basso S; Castellano S; Paolini A; Maccaferri M; Colaci E; Vallerini D; Natali P; Debbia D; Pirotti T; Ottomano AM; Maffei R; Bettelli F; Giusti D; Messerotti A; Gilioli A; Pioli V; Leonardi G; Forghieri F; Bresciani P; Cuoghi A; Morselli M; Manfredini R; Longo G; Candoni A; Marasca R; Potenza L; Tagliafico E; Trenti T; Comoli P; Luppi M; Riva G
    Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765928
    [TBL] [Abstract][Full Text] [Related]  

  • 123. TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice.
    Minnie SA; Waltner OG; Ensbey KS; Olver SD; Collinge AD; Sester DP; Schmidt CR; Legg SR; Takahashi S; Nemychenkov NS; Sekiguchi T; Driessens G; Zhang P; Koyama M; Spencer A; Holmberg LA; Furlan SN; Varelias A; Hill GR
    J Clin Invest; 2023 Feb; 133(4):. PubMed ID: 36512425
    [TBL] [Abstract][Full Text] [Related]  

  • 124. Depletion of exhausted alloreactive T cells enables targeting of stem-like memory T cells to generate tumor-specific immunity.
    Minnie SA; Waltner OG; Ensbey KS; Nemychenkov NS; Schmidt CR; Bhise SS; Legg SRW; Campoy G; Samson LD; Kuns RD; Zhou T; Huck JD; Vuckovic S; Zamora D; Yeh A; Spencer A; Koyama M; Markey KA; Lane SW; Boeckh M; Ring AM; Furlan SN; Hill GR
    Sci Immunol; 2022 Oct; 7(76):eabo3420. PubMed ID: 36240285
    [TBL] [Abstract][Full Text] [Related]  

  • 125. The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value.
    Desantis V; Savino FD; Scaringella A; Potenza MA; Nacci C; Frassanito MA; Vacca A; Montagnani M
    J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566637
    [TBL] [Abstract][Full Text] [Related]  

  • 126. The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches.
    Lagreca I; Riva G; Nasillo V; Barozzi P; Castelli I; Basso S; Bettelli F; Giusti D; Cuoghi A; Bresciani P; Messerotti A; Gilioli A; Pioli V; Colasante C; Vallerini D; Paolini A; Maccaferri M; Donatelli F; Forghieri F; Morselli M; Colaci E; Leonardi G; Marasca R; Potenza L; Manfredini R; Tagliafico E; Trenti T; Comoli P; Luppi M
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563634
    [TBL] [Abstract][Full Text] [Related]  

  • 127. The Insider: Impact of the Gut Microbiota on Cancer Immunity and Response to Therapies in Multiple Myeloma.
    Brevi A; Cogrossi LL; Lorenzoni M; Mattorre B; Bellone M
    Front Immunol; 2022; 13():845422. PubMed ID: 35371048
    [TBL] [Abstract][Full Text] [Related]  

  • 128. Prognostic impact of natural killer cell recovery on minimal residual disease after autologous stem cell transplantation in multiple myeloma.
    Keruakous AR; Asch A; Aljumaily R; Zhao D; Yuen C
    Transpl Immunol; 2022 Apr; 71():101544. PubMed ID: 35093506
    [TBL] [Abstract][Full Text] [Related]  

  • 129. T cell landscape and dynamics in immunoglobulin light chain amyloidosis before and after daratumumab-based therapy.
    Wang Y; Xu L; Zhao W; Chen X; Wen L; Duan W; Yu XJ; De Zhou F; Liu Y; Hao J; Huang X; Lu J; Ge Q
    Clin Transl Med; 2021 Nov; 11(11):e582. PubMed ID: 34845849
    [TBL] [Abstract][Full Text] [Related]  

  • 130. Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma.
    Merryman RW; Redd R; Jeter E; Wong JL; McHugh K; Reynolds C; Nazzaro M; Varden A; Brown JR; Crombie JL; Davids MS; Fisher DC; Jacobsen E; Jacobson CA; Kim AI; LaCasce AS; Ng SY; Odejide OO; Parry EM; Dahi PB; Nieto Y; Joyce RM; Chen YB; Herrera AF; Armand P; Ritz J
    Transplant Cell Ther; 2022 Jan; 28(1):32.e1-32.e10. PubMed ID: 34670169
    [TBL] [Abstract][Full Text] [Related]  

  • 131. The Impact of Induction Regimes on Immune Responses in Patients with Multiple Myeloma.
    Firer MA; Shapira MY; Luboshits G
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439244
    [TBL] [Abstract][Full Text] [Related]  

  • 132. The Cancer-Immunity Cycle in Multiple Myeloma.
    Casey M; Nakamura K
    Immunotargets Ther; 2021; 10():247-260. PubMed ID: 34295843
    [TBL] [Abstract][Full Text] [Related]  

  • 133. Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy.
    Meermeier EW; Welsh SJ; Sharik ME; Du MT; Garbitt VM; Riggs DL; Shi CX; Stein CK; Bergsagel M; Chau B; Wheeler ML; Bezman N; Wang F; Strop P; Bergsagel PL; Chesi M
    Blood Cancer Discov; 2021 Jul; 2(4):354-369. PubMed ID: 34258584
    [TBL] [Abstract][Full Text] [Related]  

  • 134. Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.
    Pisano M; Cheng Y; Sun F; Dhakal B; D'Souza A; Chhabra S; Knight JM; Rao S; Zhan F; Hari P; Janz S
    Front Immunol; 2021; 12():667054. PubMed ID: 34149703
    [TBL] [Abstract][Full Text] [Related]  

  • 135. Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
    Minnie SA; Hill GR
    Front Immunol; 2021; 12():651288. PubMed ID: 33777050
    [TBL] [Abstract][Full Text] [Related]  

  • 136. Chimeric Antigen Receptor T Cells for Multiple Myeloma: The Journey So Far-And the Road Ahead.
    Cowan AJ; Tuazon SA; Portuguese AJ; Green DJ
    Cancer J; 2021 Mar-Apr 01; 27(2):112-118. PubMed ID: 33750070
    [TBL] [Abstract][Full Text] [Related]  

  • 137. Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention.
    McCachren SS; Dhodapkar KM; Dhodapkar MV
    Front Immunol; 2021; 12():632564. PubMed ID: 33717170
    [TBL] [Abstract][Full Text] [Related]  

  • 138. Increased Immune-Regulatory Receptor Expression on Effector T Cells as Early Indicators of Relapse Following Autologous Stem Cell Transplantation for Multiple Myeloma.
    Lee L; Alrasheed N; Khandelwal G; Fitzsimons E; Richards H; Wilson W; Chavda SJ; Henry J; Conde L; De Massy MR; Chin M; Galas-Filipowicz D; Herrero J; Chain B; Quezada SA; Yong K
    Front Immunol; 2021; 12():618610. PubMed ID: 33717112
    [TBL] [Abstract][Full Text] [Related]  

  • 139. Treg and Oligoclonal Expansion of Terminal Effector CD8
    Joshua DE; Vuckovic S; Favaloro J; Lau KHA; Yang S; Bryant CE; Gibson J; Ho PJ
    Front Immunol; 2021; 12():620596. PubMed ID: 33708212
    [TBL] [Abstract][Full Text] [Related]  

  • 140. Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study.
    Khan N; Lindner S; Gomes ALC; Devlin SM; Shah GL; Sung AD; Sauter CS; Landau HJ; Dahi PB; Perales MA; Chung DJ; Lesokhin AM; Dai A; Clurman A; Slingerland JB; Slingerland AE; Brereton DG; Giardina PA; Maloy M; Armijo GK; Rondon-Clavo C; Fontana E; Bohannon L; Ramalingam S; Bush AT; Lew MV; Messina JA; Littmann E; Taur Y; Jenq RR; Chao NJ; Giralt S; Markey KA; Pamer EG; van den Brink MRM; Peled JU
    Blood; 2021 Mar; 137(11):1527-1537. PubMed ID: 33512409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.